Literature DB >> 24100266

Diabetic nephropathy: diagnosis and treatment.

Daniel Fineberg1, Karin A M Jandeleit-Dahm, Mark E Cooper.   

Abstract

Nephropathy remains a major cause of morbidity and a key determinant of mortality in patients with type 1 or type 2 diabetes mellitus. Research is ongoing to identify biomarkers that in addition to albuminuria and glomerular filtration rate assist in the prediction and monitoring of renal disease in diabetes mellitus. Current strategies to treat this condition focus on intensification of glycaemic control and excellent control of blood pressure using regimens based on blockade of the renin-angiotensin system. Other approaches to control blood pressure and afford renoprotection are under active clinical investigation, including renal denervation and endothelin receptor antagonism. With increasing understanding of the underlying pathophysiological processes implicated in diabetic nephropathy, new specific renoprotective treatment strategies are anticipated to become available over the next few years.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24100266     DOI: 10.1038/nrendo.2013.184

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN: 1759-5029            Impact factor:   43.330


  140 in total

Review 1.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

Review 2.  Mechanisms of diabetic complications.

Authors:  Josephine M Forbes; Mark E Cooper
Journal:  Physiol Rev       Date:  2013-01       Impact factor: 37.312

3.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

4.  Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.

Authors:  Giancarlo Viberti; Nigel M Wheeldon
Journal:  Circulation       Date:  2002-08-06       Impact factor: 29.690

5.  Chronic renal denervation prevents glomerular hyperfiltration in diabetic rats.

Authors:  Gerd Luippold; Martina Beilharz; Bernd Mühlbauer
Journal:  Nephrol Dial Transplant       Date:  2004-02       Impact factor: 5.992

6.  Lowering blood pressure reduces renal events in type 2 diabetes.

Authors:  Bastiaan E de Galan; Vlado Perkovic; Toshiharu Ninomiya; Avinesh Pillai; Anushka Patel; Alan Cass; Bruce Neal; Neil Poulter; Stephen Harrap; Carl-Erik Mogensen; Mark Cooper; Michel Marre; Bryan Williams; Pavel Hamet; Giuseppe Mancia; Mark Woodward; Paul Glasziou; Diederick E Grobbee; Stephen MacMahon; John Chalmers
Journal:  J Am Soc Nephrol       Date:  2009-02-18       Impact factor: 10.121

7.  Accurate estimation of glomerular filtration rate in diabetic nephropathy from age, body weight, and serum creatinine.

Authors:  M J Sampson; P L Drury
Journal:  Diabetes Care       Date:  1992-05       Impact factor: 19.112

8.  Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.

Authors:  Murray Epstein; Gordon H Williams; Myron Weinberger; Andrew Lewin; Scott Krause; Robin Mukherjee; Rajiv Patni; Bruce Beckerman
Journal:  Clin J Am Soc Nephrol       Date:  2006-07-19       Impact factor: 8.237

9.  Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Valentine Charlton-Menys; David A DeMicco; John H Fuller
Journal:  Am J Kidney Dis       Date:  2009-06-21       Impact factor: 8.860

10.  Tandem inhibition of PKC in Diαβetic nephropathy: it takes two to tango?

Authors:  Vicki Thallas-Bonke; Mark E Cooper
Journal:  Diabetes       Date:  2013-04       Impact factor: 9.461

View more
  91 in total

Review 1.  MicroRNAs in diabetic nephropathy: functions, biomarkers, and therapeutic targets.

Authors:  Mitsuo Kato; Rama Natarajan
Journal:  Ann N Y Acad Sci       Date:  2015-04-15       Impact factor: 5.691

Review 2.  Epigenetics and epigenomics in diabetic kidney disease and metabolic memory.

Authors:  Mitsuo Kato; Rama Natarajan
Journal:  Nat Rev Nephrol       Date:  2019-06       Impact factor: 28.314

3.  Adenosine kinase inhibition protects the kidney against streptozotocin-induced diabetes through anti-inflammatory and anti-oxidant mechanisms.

Authors:  Chelsey Pye; Nehal M Elsherbiny; Ahmed S Ibrahim; Gregory I Liou; Ahmed Chadli; Mohamed Al-Shabrawey; Ahmed A Elmarakby
Journal:  Pharmacol Res       Date:  2014-05-17       Impact factor: 7.658

4.  Suppressor of Cytokine Signaling-1 Peptidomimetic Limits Progression of Diabetic Nephropathy.

Authors:  Carlota Recio; Iolanda Lazaro; Ainhoa Oguiza; Laura Lopez-Sanz; Susana Bernal; Julia Blanco; Jesus Egido; Carmen Gomez-Guerrero
Journal:  J Am Soc Nephrol       Date:  2016-09-08       Impact factor: 10.121

5.  Preparation of Ergosterol-Loaded Nanostructured Lipid Carriers for Enhancing Oral Bioavailability and Antidiabetic Nephropathy Effects.

Authors:  Zhonghua Dong; Sajid Iqbal; Zhongxi Zhao
Journal:  AAPS PharmSciTech       Date:  2020-01-13       Impact factor: 3.246

6.  Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice.

Authors:  Clothilde Roche; Dominique Guerrot; Najah Harouki; Thomas Duflot; Marie Besnier; Isabelle Rémy-Jouet; Sylvanie Renet; Anaïs Dumesnil; Annie Lejeune; Christophe Morisseau; Vincent Richard; Jeremy Bellien
Journal:  Prostaglandins Other Lipid Mediat       Date:  2015-05-27       Impact factor: 3.072

Review 7.  Clinical therapeutic strategies for early stage of diabetic kidney disease.

Authors:  Munehiro Kitada; Keizo Kanasaki; Daisuke Koya
Journal:  World J Diabetes       Date:  2014-06-15

8.  KCNQ1OT1/miR-18b/HMGA2 axis regulates high glucose-induced proliferation, oxidative stress, and extracellular matrix accumulation in mesangial cells.

Authors:  Jia Li; Mingming Li; Ling Bai
Journal:  Mol Cell Biochem       Date:  2020-09-29       Impact factor: 3.396

Review 9.  A glimpse of matrix metalloproteinases in diabetic nephropathy.

Authors:  X Xu; L Xiao; P Xiao; S Yang; G Chen; F Liu; Y S Kanwar; L Sun
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

10.  The inhibition of SGK1 suppresses epithelial-mesenchymal transition and promotes renal tubular epithelial cell autophagy in diabetic nephropathy.

Authors:  Langen Zhuang; Guoxi Jin; Xiaolei Hu; Qingqing Yang; Zhaoming Shi
Journal:  Am J Transl Res       Date:  2019-08-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.